MAPT and Alzheimer disease: Previous studies reported that EGCG treatment significantly reduced Aβ generation in human-derived neuroblastoma cell line (SH-SY5Y) induced by 3-HK, in murine neuron-like cells (N2a) transfected with human “Swedish” mutant APP, and in primary neurons derived from Swedish mutant APP-overexpressing mice (TgAPPsw line 2576), and markedly improved the cognitive deficits, APP processing, and Tau pathology in D-gal-induced AD mice, TgAPPsw line 2576 transgenic mice and PS2 transgenic mice, suggesting that EGCG treatment exerted the neuroprotective effects in vitro and in vivo [23–27].